fbpx

deucravacitinib

A new drug has been approved by FDA for the treatment of plaque psoriasis

The Food and Drug Administration (FDA) hasĀ approvedĀ a new drug for the treatment of moderate to severe plaque psoriasis. About 8 million adults in the United States have psoriasis with the most common type being plaque psoriasis. The drug, called deucravacitinib, is the first TYK2 inhibitor approved for the treatment of any disease. It will be […]

Scroll to top